ENABLE: Medication brand changes in hormone therapy for breast cancer
- Conditions
- Hormone therapy for breast cancerCancer
- Registration Number
- ISRCTN15089342
- Lead Sponsor
- ondon Metropolitan University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 45
WP1 - 1.c Qualitative interviews with pharmacists:
1.Pharmacists who are owner or manager of a community pharmacy, chain and independent;
2.pharmacists with a representative role in professional pharmaceutical bodies, e.g. Local Pharmaceutical Committee, Community Pharmacy England, Royal Pharmaceutical Society.
WP2 - 2b. Qualitative interviews with pharmacists:
1.A pharmacist or pharmacist technician, permanent or locum (and)
2.Working in community pharmacies located in London (and)
3.Providing hormone therapy medication to clients
WP3 – Testing and optimisation studies
Pharmacists:
1.Pharmacists and pharmacy technicians; from the London boroughs of Barnet, Camden, Enfield, Haringey, or Islington
2.Providing Hormone Therapy medication to clients
3.Agree to participate in online training
4.Agree to recruit 4 patients from their pharmacy
5.Agree to deliver a medication consultation with recruited participants and audio record 1 consultation (with patient consent), and provide feedback notes of the consultation.
6.Agree to provide feedback in a study follow-up interview.
7.Is willing to provide written (signed and dated) informed consent.
Patients:
1.Women 18+ with early BC (stage 1-3);
2.Talking oral HT medication (tamoxifen, anastrozole, or letrozole) and had/have concerns about changing HT brands;
3.Not taking HT medication as neo-adjuvant or secondary metastatic BC;
4.Is willing and able to record notes on side effects and medication taken (diary) and attend a medication consultation with the CP;
5.Is willing and able to participate in a study follow-up interview (phone or video conference);
6.Is willing to provide a copy of the diary;
7.Is willing to be audio recorded during the pharmacy consultation;
8.Is willing to provide written (signed and dated) informed consent.
WP1 - 1.c Qualitative interviews with pharmacists:
1.locum, technician, assistants, pharmacist not owner or manager
2.Pharmacists without a representative role in professional pharmaceutical bodies
WP2 - 2b. Qualitative interviews with pharmacists:
1.Accredited Checking Technician, assistants
WP3 – Testing and optimisation studies
Pharmacists:
1.Locum, Accredited Checking Technician, pharmacy assistants.
Patients:
1.Male
2.Currently or recently (last 6 months) involved in another research study where medication adherence is a primary outcome;
3.Have had in the last 6 months a medication review about changing brands of HT drugs.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Qualitative interviews to optimise the usability, practicality and acceptability of the intervention for community pharmacists and breast cancer patients. Using behavioural analysis constructs from the Theoretical Domains Framework and the Person-Based Approach for intervention development conducted 2 or 3 weeks after the testing of the intervention in WP3
- Secondary Outcome Measures
Name Time Method There are no secondary outcome measures